Medindia1mon
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
Beyond first-line approval, the phase III clinical study (AK109-301) of cadonilimab combined with pulocimab (AK109, VEGFR-2) for treating advanced gastric cancer that has progressed after PD-1/L1 ...
Wall Street Journal6d
Sabine Royalty Trust UBI
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Benzinga.com4y
Sabine Royalty (NYSE:SBR) Stock Quotes, Forecast and News Summary
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Applied Therapeutics, Inc. Avi Kapoor Passive Income Ideas For ...
Nasdaq4y
Sabine Royalty Trust Common Stock (SBR) Dividend History
The Dividend History page provides a single page to review all of the aggregated Dividend payment information. Visit our Dividend Calendar: Please note that the dividend history for Nasdaq stocks ...
Yahoo Finance1mon
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population
Beyond first-line approval, the phase III clinical study (AK109-301) of cadonilimab combined with pulocimab (AK109, VEGFR-2) for treating advanced gastric cancer that has progressed after PD-1/L1 ...